GuruFocus.com1d agobearish
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger TalksInvestors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
493last 24h
2476last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
Pharmaceutical Technology1d agobearish
AstraZeneca shares slump after $400bn BMS merger rumoursOne of the largest global pharma companies would be created if a deal were to materialise.
Barrons.com2d agobearish
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZenecaThe merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.
The Wall Street Journal2d agobearish
U.S. Stock Futures Rise, Oil Falls as U.S. Shifts Toward Diplomacy with IranU.S. stocks were on track to extend Friday’s rally as President Trump said he had canceled planned strikes on Iran, adding that peace talks would resume Monday afternoon.
The Wall Street Journal2d agobearish
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger TalksIf maintained until close, the decline would be the stock’s biggest one-day percentage fall since the day of the 2024 U.S. presidential election.
Reuters36d agobearish
Exclusive-US House committee opens investigation into Merck, AbbVie China drug trialsJune 30 (Reuters) - A bipartisan group of U. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved in clinical trials conducted in China that helped fuel the communist country's military capability, according to letters seen by Reuters.
The Wall Street Journal79d agobearish
Regeneron Stock Tumbles on Melanoma Drug-Trial MissShares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.
The Wall Street Journal79d agobearish
Regeneron Melanoma Drug Trial Disappoints and Shares SlideShares tumbled after the drugmaker said a late-stage clinical trial of a skin cancer medication fell short of its target.